I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Neuroblastoma (NB), the most common extracranial solid tumor of childhood, accounts for 8--10% of all childhood cancers and is responsible for about 15% of all pediatric oncology-related deaths.\[[@ref1][@ref2]\] Although the etiology and pathogenesis of NB are largely unknown, accumulating evidence shows that genetic polymorphisms contribute to NB susceptibility. Jin *et al*.\[[@ref3]\] reported that the single nucleotide polymorphisms (SNPs) rs11669203 in *TGFBR3L* is associated with the risk of NB in a Chinese population. Mossé *et al*.\[[@ref4]\] reported that individuals carrying germline mutations in *PHOX2B* are genetically predisposed to NB. The Genome-wide Association Study demonstrated that genetic variations in the *CASC15*, *BARD1*, *LMO1*, *DUSP12*, *HSD17B12*, *HACE1*, and *LIN28B* genes are associated with NB risk in North American patients of European descent.\[[@ref5][@ref6][@ref7][@ref8][@ref9]\]

Interleukin-6 (IL-6) facilitates the progression of several cancers\[[@ref10][@ref11][@ref12][@ref13]\] by affecting several biological mechanisms and cellular processes, including apoptosis, survival, proliferation, angiogenesis, invasiveness, metastasis, and metabolism.\[[@ref14]\] Elevated serum IL-6 level has been shown to correlate with NB progression and development,\[[@ref15]\] and to promote growth and survival of NB cells in the bone marrow.\[[@ref16]\] In recent years, reports have shown that the polymorphism rs1800795, which is located in the IL-6 promoter region, affects the constitutive transcription of the IL-6 gene, thereby controlling the level of IL-6. Results showing a close relationship of rs1800795 SNP to NB are inconsistent.\[[@ref17][@ref18]\] Furthermore, none of these reports has dealt with Chinese NB patients. Consequently, we conducted a case-control study to examine the relationship of IL-6 level and rs1800795 SNP status to the risk of NB in China.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Ethics statement {#sec2-1}
----------------

This study is approved by the Research Ethics Committee at the Beijing Children\'s Hospital and written informed consent was obtained by all children\'s legal guardians according to the *Declaration of Helsinki*.

Study population {#sec2-2}
----------------

A total of 130 patients with histopathologically confirmed NB were recruited from the Beijing Children\'s Hospital between August 2012 and August 2015 (77 boys, 53 girls; mean age: 41 ± 5 months). The NB for each patient was staged by at least two pathologists according to the International Neuroblastoma Staging System. During the same period, 50 healthy children were randomly selected as age- and gender-matched controls after receiving a routine physical examination (28 boys, 22 girls; mean age: 39 ± 6 months). Both the cases and the controls were unrelated ethnic Chinese Han individuals, and all were born in North China. Clinical and biologic characteristics of the patients are shown in [Table 1](#T1){ref-type="table"}. Patients were assigned to two risk groups based on the Children\'s Oncology Group risk assignment algorithm.\[[@ref19]\]

###### 

Characteristics and clinical features of all subjects, *n* (%)

  Characteristics   Controls (*n* = 50)   NB patients (*n* = 130)
  ----------------- --------------------- -------------------------
  Gender                                  
    Boy             28 (56.0)             77 (59.2)
    Girl            22 (44.0)             53 (40.8)
  Age                                     
    ≤18 months      19 (38.0)             34 (26.2)
    \>18 months     31 (62.0)             96 (73.8)
  Risk                                    
    HR                                    87 (66.9)
    Non-HR                                43 (33.1)

HR: High risk; NB: Neuroblastoma.

Patient samples {#sec2-3}
---------------

Peripheral blood samples were drawn in ethylenediaminetetraacetic acid-containing vacuum tubes from 130 patients with NB when newly diagnosed before any treatment, and 50 cancer-free Chinese children selected as sex- and age-matched normal controls after a fast of more than 8 h. Genomic DNA was extracted from peripheral blood leukocytes using a commercial DNA isolation kit according to the manufacturer\'s instructions. The IL-6 rs1800795 polymorphism was genotyped by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry using the Sequenom MassARRAY according to the manufacturer\'s instructions. The forward and reverse genotyping primers were: 5\'-ATGCCAAGTGCTGAGTCACTA-3\' and 5\'-TCGAGGGCAGAATGAGCCTC-3\'.

Serum levels of IL-6 were determined in triplicate samples by ELISA according to the manufacturer\'s protocol (Quantikine immune assay kit, R&D Systems, Minneapolis, MN, USA).

Statistical analysis {#sec2-4}
--------------------

To evaluate the potential deviation from Hardy-Weinberg equilibrium, we compared the obtained and expected allele frequencies in the case and control samples using a Chi-square test. To evaluate the association between cases or controls and the presence of polymorphism, we used unconditional multiple logistic regression to estimate odds ratios (*OR*s) with 95% confidence intervals (*CI*s). To decide whether to accept or reject the null hypothesis, we used the likelihood ratio statistic with 95% *CI* (*P* \< 0.05) calculated for adjusted *OR*. Statistical analyses were carried out using SPSS 16.0 software (IBM Corp., Armonk, NY, USA). A *P* \< 0.05 was considered as statistically significant.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Characteristics and clinical features {#sec2-5}
-------------------------------------

As shown in [Table 1](#T1){ref-type="table"}, the current study included 130 cases of NB and 50 age-, gender-, and ethnicity-matched controls. The patients were treated and followed up at Beijing Children\'s Hospital. In the NB group, the primary tumors were in the retroperitoneal space in 111 cases (85.4%) and posterior mediastinum in 19 cases (14.6%). The metastases were in the bone marrow in 84 patients (64.6%), bone in 52 patients (40.0%), liver in 5 patients (3.8%), skin in 3 patients (2.3%), and lung in 1 patient (0.7%). The *MYCN* was amplified in 11 patients and nonamplified in 47 patients.

Relationship of rs1800795 single nucleotide polymorphisms between neuroblastoma cases and controls {#sec2-6}
--------------------------------------------------------------------------------------------------

A summary of the genotype and allele distribution of the rs1800795 polymorphisms in the NB patients and controls is shown in [Table 2](#T2){ref-type="table"}. The genotype and allele frequencies of the rs1800795 locus were similar between NB patients and controls (*P* \> 0.05).

###### 

Case-control study of rs1800795 SNP, *n* (%)

  Items      Controls (*n* = 50)   NB patients (*n* = 130)   *P*    *OR* (95% *CI*)
  ---------- --------------------- ------------------------- ------ -------------------
  Genotype                                                          
    GG       26 (52.0)             77 (59.2)                 --     --
    GC       19 (38.0)             42 (32.3)                 0.26   1.29 (0.87--1.91)
    CC       5 (10.0)              11 (8.4)                  0.12   1.35 (0.96--1.92)
    GG/GC    45 (90.0)             119 (91.5)                --     --
    CC       5 (10.0)              11 (8.4)                  0.09   1.56 (0.89--2.04)
  Allele                                                            
    G        71 (71.0)             196 (75.0)                --     --
    C        29 (29.0)             64 (25.0)                 0.07   1.61 (0.87--2.21)

NB: Neuroblastoma; *OR*: Odds ratio; *CI*: Confidence interval; SNP: Single nucleotide polymorphism; --: Not applicable.

Relationship between the rs1800795 single nucleotide polymorphisms and neuroblastoma risk and *MYCN* gene amplification status {#sec2-7}
------------------------------------------------------------------------------------------------------------------------------

The GG+GC genotype frequency was compared to CC genotype frequency in NB children with different NB risk level and different MYCN gene amplification status. [Table 3](#T3){ref-type="table"} shows that frequency of GG+GC genotype was significantly higher in the high risk (HR) group (*P* \< 0.05) but similar in groups categorized by *MYCN* amplification status (*P* \> 0.05).

###### 

Relationship between rs1800795 SNP and NB risk and *MYCN* status

  Items            *n*   GG + GC genotype, *n* (%)   CC genotype, *n* (%)
  ---------------- ----- --------------------------- ----------------------
  Risk                                               
    HR             87    56 (64.4)                   31 (35.6)
    Non-HR         43    21 (48.8)                   22 (51.2)
    *P*                  0.02                        0.56
  *MYCN*                                             
    Amplified      11    2 (18.2)                    9 (81.8)
    Nonamplified   47    11 (23.4)                   36 (76.6)
    NA             72    22 (30.6)                   50 (69.4)
    *P*\*                0.16                        0.25

\*Compared in amplified and nonamplified group. NA: Not available; NB: Neuroblastoma; HR: High risk; SNP: Single nucleotide polymorphism.

Relationship between rs1800795 single nucleotide polymorphisms and serum interleukin-6 level in different neuroblastoma-risk groups and *MYCN* gene amplification status groups {#sec2-8}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In high NB risk patients (the HR group), serum IL-6 level was obviously higher in the GG+GC genotype group than in the CC genotype group (4.36 ± 1.10 pg/ml vs. 1.83 ± 0.50 pg/ml; *P* = 0.02), while no obvious difference was found in the non-HR group (2.13 ± 0.80 pg/ml vs. 1.53 ± 0.60 pg/ml; *P* = 0.19). In addition, serum IL-6 level was similar between the genotypes with amplified *MYCN* gene (2.56 ± 0.70 pg/ml vs. 2.05 ± 0.90 pg/ml; *P* = 0.16) and nonamplified *MYCN* gene (2.81 ± 0.60 pg/ml vs. 1.26 ± 0.50 pg/ml; *P* = 0.27).

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

Previous studies have linked rs1800795 SNP in the IL-6 promoter to the occurrence of a variety of tumors.\[[@ref20]\] Some recent studies have focused on the relationship of rs1800795 SNP to the occurrence of childhood NB. Lagmay *et al*.\[[@ref17]\] showed that the GG genotype of the IL-6 rs1800795 SNP is responsible for the worse outcome in patients with HR for NB. However, Totaro *et al*.\[[@ref18]\] stated that this SNP does not predispose to NB development but is associated with NB progression. They found that Italian patients with NB who were homozygous for the C allele had worse outcomes than patients who were homozygous or heterozygous for the G allele. The data from our genetic study to assess the association between IL-6 rs1800795 SNP and NB in Chinese children suggested that this SNP does not predispose to NB development but is associated with the level of NB risk. In our Chinese NB patients, the ratio of GG+GC genotype was higher in the HR-NB group than non-HR-NB group, which is consistent with Lagmay\'s conclusion. Racial differences might account for the differences between results; so, further investigations with larger samples of patients are needed.

The *MYCN* gene codes for an oncogenic transcription factor and belongs to the MYC family of genes. *MYCN* gene is amplified in approximately 20% of all NB cases, and amplified *MYCN* gene is considered to be a molecular marker identifying individuals with HR of NB. *MYCN* gene was amplified in 11 of our 130 NB patients, but nonamplified in 47 patients. *MYCN* gene amplification status was unavailable in the remaining 72 patients. Our study aimed to determine whether *MYCN* gene amplification and the IL-6 SNP of rs1800795 have a synergistic relationship but found no combination of factors significantly affected serum IL-6 level.

Many recent articles have identified the elevated level of circulating IL-6 as a marker of poor prognosis in various cancers, including NB. In Egler\'s research,\[[@ref15]\] serum IL-6 level was higher in patients with HR-NB than in those with non-HR-NB. Furthermore, in our research with a focus on the serum IL-6 level--rs1800795 SNP relationship, IL-6 level was higher in HR-NB patients with GG+GC genotype than in HR-NB patients with CC genotype, which is consistent with the conclusion of Fishman *et al*.\[[@ref21]\]

In conclusion in our research, the SNP rs1800795 was associated with serum IL-6 level and level of NB risk. GG genotype might indicate that a tumor is highly malignant (prone to spread) and associated with poor prognosis. Since rs1800795 is located in the promoter region of IL-6, we suggest that genetic variants of rs1800795 might influence serum IL-6 level. However, additional investigations are needed to confirm this hypothesis.
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